Why safety matters (i.e. "Over 680 patients dosed
Post# of 30067
Posted On: 02/05/2015 11:02:10 PM
Why safety matters (i.e. "Over 680 patients dosed to date, with strong safety profile" )
Adamas' Lead Drug Targets Parkinson's Dyskinesia - Feb. 2, 2015
"Amarantus (OTCQB:AMBS) is working with the Food and Drug Administration on the design of a phase IIb trial for eltoprazine , an agent targeting serotonin. Preliminary results have been positive, reducing dyskinesia by 10% to 15%. Thus, while there is no drug currently approved as a specific treatment for dyskinesia, there are multiple initiatives headed toward that goal."
Competitive Landscape
"Other companies and researchers are pursuing a way to control dyskinesia. Adamas hopes to stay ahead of the pack. The Michael J. Fox Foundation lists 5 such efforts that they are supporting or have supported in the past. Some appear to have reached a plateau which in the biotech world is often between a successful phase II and an expensive phase III trial when companies consider how to encourage others as partners to participate financially in the next step."
"Adamas Pharmaceuticals (NASDAQ:ADMS) seeks to remedy this condition by using a control release version of amantadine, a treatment for levodopa induced dyskinesia (LID). Why a control release? Because amantadine can cause leg swelling, hallucinations and unusual dreams at night if taken at higher concentrations. A control release can presumably release smaller amounts in increments over time once the pill is ingested. The Adamas 10-K describes this effort:"
http://seekingalpha.com/article/2876136-adama...dyskinesia
Adamas' Lead Drug Targets Parkinson's Dyskinesia - Feb. 2, 2015
"Amarantus (OTCQB:AMBS) is working with the Food and Drug Administration on the design of a phase IIb trial for eltoprazine , an agent targeting serotonin. Preliminary results have been positive, reducing dyskinesia by 10% to 15%. Thus, while there is no drug currently approved as a specific treatment for dyskinesia, there are multiple initiatives headed toward that goal."
Competitive Landscape
"Other companies and researchers are pursuing a way to control dyskinesia. Adamas hopes to stay ahead of the pack. The Michael J. Fox Foundation lists 5 such efforts that they are supporting or have supported in the past. Some appear to have reached a plateau which in the biotech world is often between a successful phase II and an expensive phase III trial when companies consider how to encourage others as partners to participate financially in the next step."
"Adamas Pharmaceuticals (NASDAQ:ADMS) seeks to remedy this condition by using a control release version of amantadine, a treatment for levodopa induced dyskinesia (LID). Why a control release? Because amantadine can cause leg swelling, hallucinations and unusual dreams at night if taken at higher concentrations. A control release can presumably release smaller amounts in increments over time once the pill is ingested. The Adamas 10-K describes this effort:"
http://seekingalpha.com/article/2876136-adama...dyskinesia
(0)
(0)